Related Experiment Video
Updated: Aug 16, 2025

An Ex vivo Model to Study Hormone Action in the Human Breast
Published on: January 8, 2015
Targeting the Progesterone Receptor in Breast Cancer: Mind the Short Form!
Carlos Ronchi1, Cathrin Brisken1,2
1ISREC - Swiss Institute for Experimental Cancer Research, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.
Summary:
The presurgical window of opportunity trial (WOT) MIPRA provides evidence that neoadjuvant treatment with the progesterone receptor (PR) antagonist mifepristone (RU486) may benefit patients with estrogen receptor-positive (ER+) breast cancer characterized by a high ratio of PR-A versus PR-B isoform (>1.5), suggesting that PR may be targeted in a subset of patients. See related article by Elía et al., p. 866.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Mitogens and the Cell Cycle

